Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice - PubMed (original) (raw)
Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice
Sean P Dineen et al. Cancer Res. 2008.
Abstract
Macrophages are an abundant inflammatory cell type in the tumor microenvironment that can contribute to tumor growth and metastasis. Macrophage recruitment into tumors is mediated by multiple cytokines, including vascular endothelial growth factor (VEGF), which is thought to function primarily through VEGF receptor (VEGFR) 1 expressed on macrophages. Macrophage infiltration is affected by VEGF inhibition. We show that selective inhibition of VEGFR2 reduced macrophage infiltration into orthotopic pancreatic tumors. Our studies show that tumor-associated macrophages express VEGFR2. Furthermore, peritoneal macrophages from tumor-bearing animals express VEGFR2, whereas peritoneal macrophages from non-tumor-bearing animals do not. To our knowledge, this is the first time that tumor-associated macrophages have been shown to express VEGFR2. Additionally, we found that the cytokine pleiotrophin is sufficient to induce VEGFR2 expression on macrophages. Pleiotrophin has previously been shown to induce expression of endothelial cell markers on macrophages and was present in the microenvironment of orthotopic pancreatic tumors. Finally, we show that VEGFR2, when expressed by macrophages, is essential for VEGF-stimulated migration of tumor-associated macrophages. In summary, tumor-associated macrophages express VEGFR2, and selective inhibition of VEGFR2 reduces recruitment of macrophages into orthotopic pancreatic tumors. Our results show an underappreciated mechanism of action that may directly contribute to the antitumor activity of angiogenesis inhibitors that block the VEGFR2 pathway.
Similar articles
- Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, Sullivan JP, Shames DS, Brekken RA. Roland CL, et al. Mol Cancer Ther. 2009 Jul;8(7):1761-71. doi: 10.1158/1535-7163.MCT-09-0280. Epub 2009 Jun 30. Mol Cancer Ther. 2009. PMID: 19567820 - Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes.
Lang SA, Schachtschneider P, Moser C, Mori A, Hackl C, Gaumann A, Batt D, Schlitt HJ, Geissler EK, Stoeltzing O. Lang SA, et al. Mol Cancer Ther. 2008 Nov;7(11):3509-18. doi: 10.1158/1535-7163.MCT-08-0373. Mol Cancer Ther. 2008. PMID: 19001434 - Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines.
Fukasawa M, Korc M. Fukasawa M, et al. Clin Cancer Res. 2004 May 15;10(10):3327-32. doi: 10.1158/1078-0432.CCR-03-0820. Clin Cancer Res. 2004. PMID: 15161686 - Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis.
Shibuya M. Shibuya M. J Biochem Mol Biol. 2006 Sep 30;39(5):469-78. doi: 10.5483/bmbrep.2006.39.5.469. J Biochem Mol Biol. 2006. PMID: 17002866 Review.
Cited by
- Immunotherapies Targeting Tumor-Associated Macrophages (TAMs) in Cancer.
Li MY, Ye W, Luo KW. Li MY, et al. Pharmaceutics. 2024 Jun 27;16(7):865. doi: 10.3390/pharmaceutics16070865. Pharmaceutics. 2024. PMID: 39065562 Free PMC article. Review. - Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma.
Le Saux O, Ardin M, Berthet J, Barrin S, Bourhis M, Cinier J, Lounici Y, Treilleux I, Just PA, Bataillon G, Savoye AM, Mouret-Reynier MA, Coquan E, Derbel O, Jeay L, Bouizaguen S, Labidi-Galy I, Tabone-Eglinger S, Ferrari A, Thomas E, Ménétrier-Caux C, Tartour E, Galy-Fauroux I, Stern MH, Terme M, Caux C, Dubois B, Ray-Coquard I. Le Saux O, et al. Nat Commun. 2024 Jul 16;15(1):5932. doi: 10.1038/s41467-024-47000-5. Nat Commun. 2024. PMID: 39013886 Free PMC article. Clinical Trial. - Current and future immunotherapeutic approaches in pancreatic cancer treatment.
Farhangnia P, Khorramdelazad H, Nickho H, Delbandi AA. Farhangnia P, et al. J Hematol Oncol. 2024 Jun 4;17(1):40. doi: 10.1186/s13045-024-01561-6. J Hematol Oncol. 2024. PMID: 38835055 Free PMC article. Review. - ORF virus causes tumor-promoting inflammation in sheep and goats.
Pintus D, Cancedda MG, Puggioni G, Scivoli R, Rocchigiani AM, Maestrale C, Coradduzza E, Bechere R, Silva-Flannery L, Bullock HA, Macciocu S, Montesu MA, Marras V, Dore S, Ritter JM, Ligios C. Pintus D, et al. Vet Pathol. 2024 Sep;61(5):803-814. doi: 10.1177/03009858241241794. Epub 2024 Apr 13. Vet Pathol. 2024. PMID: 38613413 Free PMC article. - VEGFR-3 signaling in macrophages: friend or foe in disease?
Kannan S, Rutkowski JM. Kannan S, et al. Front Immunol. 2024 Feb 22;15:1349500. doi: 10.3389/fimmu.2024.1349500. eCollection 2024. Front Immunol. 2024. PMID: 38464522 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical